Using viable adriamycin resistant human ovarian carcinoma cells 2780AD and colchicine resistant human oral epidermoid carcinoma cells KB-24 as the immunogen in primary and subsequent i.p. immunizations, followed by i.v. boostings with crude plasma membranes of 2780AD, KB-24, Chinese hamster
Developing novel approaches to reverse the drug resistance of tumor-repopulating cells (TRCs) or stem cell-like cancer cells is an urgent clinical need to improve outcomes of cancer patients. Here we show an innovative approach that reverses drug resistance of TRCs
Biochemical and biophysical research communications, 203(1), 506-512 (1994-08-30)
Multidrug resistance (MDR) is a unique phenomenon in cancer patients and is commonly associated with an overexpression of the human MDR gene mdr1, which encodes an energy-dependent Mr 180 kDa membrane bound protein, known as P-glycoprotein. P-glycoprotein serves as a
Di-2-pyridylketone 4, 4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug-Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp).
Jansson P J, et al.
The Journal of Biological Chemistry (2015)
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
